Safia Chatur
Overview
Explore the profile of Safia Chatur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cunningham J, Chatur S, Claggett B, Vaduganathan M, Desai A, Jhund P, et al.
JAMA Cardiol
. 2025 Feb;
PMID: 40009358
Importance: Worsening heart failure (HF) is commonly managed in the outpatient setting with adjustments in oral diuretic therapy. The effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on outpatient worsening...
2.
Chatur S, Seth M, Casey M, Thompson M, Thompson M, Qureshi M, et al.
Am Heart J
. 2025 Feb;
285:12-20.
PMID: 39988205
Background: Despite the robust clinical evidence base supporting their role for high-risk patients with type 2 diabetes (T2DM) and concomitant cardiovascular disease, prescription of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like...
3.
Chatur S, Vaduganathan M, Fletcher R, Perkovic V, Heerspink H, Arnott C, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39844714
Aims: The sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes...
4.
5.
Wang X, Vardeny O, Claggett B, Vaduganathan M, Hegde S, Skali H, et al.
Eur J Heart Fail
. 2024 Dec;
27(1):96-106.
PMID: 39675788
Aims: To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial. Methods And Results: A total of...
6.
Hojbjerg Lassen M, Johansen N, Vaduganathan M, Bhatt A, Modin D, Chatur S, et al.
JACC Adv
. 2024 Nov;
3(12):101391.
PMID: 39606218
Background: Despite evidence demonstrating that influenza vaccination is associated with reduced risk of cardiovascular events and all-cause mortality in individuals with diabetes mellitus (DM), vaccine uptake remains suboptimal. Objectives: The...
7.
Bhatt A, Johansen N, Vaduganathan M, Modin D, Pareek M, Chatur S, et al.
JAMA Cardiol
. 2024 Nov;
10(1):78-86.
PMID: 39550717
Importance: Influenza vaccination in patients with acute myocardial infarction (AMI) reduces major adverse cardiac events and is strongly recommended in clinical practice guidelines. Effective strategies to improve vaccination are needed...
8.
Johansen N, Vaduganathan M, Bhatt A, Modin D, Chatur S, Claggett B, et al.
JAMA
. 2024 Oct;
332(22):1900-1911.
PMID: 39392741
Importance: Despite strong worldwide guideline recommendations, influenza vaccination rates remain suboptimal among young and middle-aged patients with chronic diseases. Effective scalable strategies to increase vaccination are needed. Objective: To investigate...
9.
Pabon M, Vaduganathan M, Claggett B, Chatur S, Siqueira S, Marti-Castellote P, et al.
Eur J Heart Fail
. 2024 Sep;
26(12):2532-2540.
PMID: 39300780
Aims: Patients with heart failure (HF) with improved ejection fraction (HFimpEF) may face residual risks of clinical events that are comparable to those experienced by patients with HF whose left...
10.
Neuen B, Ostrominski J, Claggett B, Beldhuis I, Chatur S, McCausland F, et al.
J Am Coll Cardiol
. 2024 Sep;
84(22):2246-2250.
PMID: 39217558
No abstract available.